Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

672 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Perianal Crohn's disease: classification and clinical evaluation.
Vermeire S, Van Assche G, Rutgeerts P. Vermeire S, et al. Dig Liver Dis. 2007 Oct;39(10):959-62. doi: 10.1016/j.dld.2007.07.153. Epub 2007 Aug 27. Dig Liver Dis. 2007. PMID: 17720634 Review.
Primary lesions include Crohn's fissures and cavitating perianal ulcers. Secondary lesions include deep abscesses, fistulas and strictures. ...This review analyses and discusses current classifications of any perianal form of Crohn's disease....
Primary lesions include Crohn's fissures and cavitating perianal ulcers. Secondary lesions include deep abscesses, fistulas and stric …
Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.
Vande Casteele N, Feagan BG, Vermeire S, Yassine M, Coarse J, Kosutic G, Sandborn WJ. Vande Casteele N, et al. Aliment Pharmacol Ther. 2018 Jan;47(2):229-237. doi: 10.1111/apt.14421. Epub 2017 Nov 21. Aliment Pharmacol Ther. 2018. PMID: 29159893 Free PMC article.
BACKGROUND: Therapeutic drug monitoring may optimize therapy for Crohn's disease (CD). AIM: To use a population pharmacokinetic model that accounts for the time-varying nature of covariates to simulate certolizumab pegol (CZP) concentrations to evaluate the exposure-respon …
BACKGROUND: Therapeutic drug monitoring may optimize therapy for Crohn's disease (CD). AIM: To use a population pharmacokinetic model …
Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.
Van Steenbergen S, Bian S, Vermeire S, Van Assche G, Gils A, Ferrante M. Van Steenbergen S, et al. Aliment Pharmacol Ther. 2017 Apr;45(7):923-932. doi: 10.1111/apt.13964. Epub 2017 Feb 6. Aliment Pharmacol Ther. 2017. PMID: 28164321
BACKGROUND: Data on dose de-escalation in patients with Crohn's disease (CD) are limited. AIM: To evaluate outcomes of dose de-escalation from adalimumab (ADM) every other week (EOW) to every three weeks (ETW). ...
BACKGROUND: Data on dose de-escalation in patients with Crohn's disease (CD) are limited. AIM: To evaluate outcomes of dose de-escala …
Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience.
Billiet T, Cleynen I, Ballet V, Ferrante M, Van Assche G, Gils A, Vermeire S. Billiet T, et al. Aliment Pharmacol Ther. 2016 Oct;44(7):673-83. doi: 10.1111/apt.13754. Epub 2016 Aug 9. Aliment Pharmacol Ther. 2016. PMID: 27502581
BACKGROUND: The long-term efficacy of infliximab in patients with Crohn's disease is suboptimal. AIM: To study prognostic factors for real-life long-term effcacy of infliximab in Crohn's disease. METHODS: All consecutive Crohn's disease patients treated with …
BACKGROUND: The long-term efficacy of infliximab in patients with Crohn's disease is suboptimal. AIM: To study prognostic factors for …
Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.
Feagan BG, Sandborn WJ, D'Haens G, Lee SD, Allez M, Fedorak RN, Seidler U, Vermeire S, Lawrance IC, Maroney AC, Jurgensen CH, Heath A, Chang DJ. Feagan BG, et al. Aliment Pharmacol Ther. 2015 Nov;42(10):1170-81. doi: 10.1111/apt.13398. Epub 2015 Sep 23. Aliment Pharmacol Ther. 2015. PMID: 26400458 Clinical Trial.
BACKGROUND: Many patients with active Crohn's disease do not adequately respond to therapies, highlighting the need for new treatments. ...CONCLUSIONS: We did not demonstrate efficacy of vercirnon as an induction therapy in patients with moderately-to-severely active Crohn …
BACKGROUND: Many patients with active Crohn's disease do not adequately respond to therapies, highlighting the need for new treatment …
Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease.
Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, Poulain D, Bossuyt X, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Esters N, et al. Am J Gastroenterol. 2002 Jun;97(6):1458-62. doi: 10.1111/j.1572-0241.2002.05689.x. Am J Gastroenterol. 2002. PMID: 12094865
OBJECTIVES: The use of monoclonal anti-tumor necrosis factor (TNF) antibodies (infliximab, Remicade) is a new therapeutic approach for severe refractory luminal or fistulizing, Crohn's disease (CD). ...Our aim was to determine whether serological markers ASCA (anti-Sacchar …
OBJECTIVES: The use of monoclonal anti-tumor necrosis factor (TNF) antibodies (infliximab, Remicade) is a new therapeutic approach for sever …
Commentary: BMI and the need for adalimumab dose escalation in Crohn's disease.
Van Assche G, Baert F, Vermeire S. Van Assche G, et al. Aliment Pharmacol Ther. 2012 Apr;35(7):848; discussion 849. doi: 10.1111/j.1365-2036.2012.05023.x. Aliment Pharmacol Ther. 2012. PMID: 22404407 No abstract available.
The changing face of treatment for Crohn's disease.
Vermeire S, Rutgeerts P. Vermeire S, et al. Br J Surg. 2006 Apr;93(4):385-6. doi: 10.1002/bjs.5272. Br J Surg. 2006. PMID: 16555241 No abstract available.
The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
Persoons P, Vermeire S, Demyttenaere K, Fischler B, Vandenberghe J, Van Oudenhove L, Pierik M, Hlavaty T, Van Assche G, Noman M, Rutgeerts P. Persoons P, et al. Aliment Pharmacol Ther. 2005 Jul 15;22(2):101-10. doi: 10.1111/j.1365-2036.2005.02535.x. Aliment Pharmacol Ther. 2005. PMID: 16011668
Strong evidence of such a mediating role of major depressive disorder in Crohn's disease has never been found. AIM: To assess the relationship between major depressive disorder and outcome of treatment of luminal Crohn's disease with infliximab. ...Assessment and ma …
Strong evidence of such a mediating role of major depressive disorder in Crohn's disease has never been found. AIM: To assess the rel …
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease.
Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Franchimont D, Fiasse R, Pelckmans P, Malaise M, Belaiche J, Louis E. Franchimont N, et al. Aliment Pharmacol Ther. 2004 Sep 15;20(6):607-14. doi: 10.1111/j.1365-2036.2004.02152.x. Aliment Pharmacol Ther. 2004. PMID: 15352908 Clinical Trial.
BACKGROUND: Crohn's disease is associated with low bone mineral density and altered bone metabolism. AIM: To assess the evolution of bone metabolism in Crohn's disease patients treated with infliximab. ...CONCLUSION: Infliximab therapy in Crohn's disease may …
BACKGROUND: Crohn's disease is associated with low bone mineral density and altered bone metabolism. AIM: To assess the evolution of …
672 results
Jump to page
Feedback